Another approach used a panel of potential serum biomarkers; epidermal growth factor receptor (EGFR), pro-ApoA1, ApoA1, transthyretin (TTR), regulated upon activation, normally T-expressed and presumably secreted (RANTES), D-dimer, vitronectin (VN), interleukin-6 (IL-6), α-2 macroglobulin, C-reactive protein (CRP), and plasminogen activator inhibitor-1 (PAI-I) were selected as classifiers in the two algorithms that accurately differentiated between the majority of gastric adenocarcinoma and control serum samples [197]. The gene discussed is CCL5; the disease is gastric adenocarcinoma.